標(biāo)題: Titlebook: Comprehensive lipid testing and management; Lars A. Carlson Book 2011 Springer Healthcare 2011 Cholestrol.Coronary heart disease.Diabetes. [打印本頁(yè)] 作者: frustrate 時(shí)間: 2025-3-21 16:55
書(shū)目名稱(chēng)Comprehensive lipid testing and management影響因子(影響力)
書(shū)目名稱(chēng)Comprehensive lipid testing and management影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Comprehensive lipid testing and management網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Comprehensive lipid testing and management網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Comprehensive lipid testing and management被引頻次
書(shū)目名稱(chēng)Comprehensive lipid testing and management被引頻次學(xué)科排名
書(shū)目名稱(chēng)Comprehensive lipid testing and management年度引用
書(shū)目名稱(chēng)Comprehensive lipid testing and management年度引用學(xué)科排名
書(shū)目名稱(chēng)Comprehensive lipid testing and management讀者反饋
書(shū)目名稱(chēng)Comprehensive lipid testing and management讀者反饋學(xué)科排名
作者: Ornithologist 時(shí)間: 2025-3-21 20:20 作者: 使饑餓 時(shí)間: 2025-3-22 02:15
Lipid profiless to determine LDL-C and HDL-C became available in routine clinical practice. Subsequently, attempts to advance the evaluation of risk for clinical atherosclerosis have continued, in order to improve prevention and treatment of the disease. In this respect, as described later in this chapter, two ma作者: acheon 時(shí)間: 2025-3-22 07:22
Lipid testing and prediction of coronary heart diseaseerol, blood pressure, smoking and diabetes [14]. Risk prediction based on Framingham data was improved in the 1980s by addition of the ‘negative’ lipid risk factor HDL-C [15]. Subsequently, there have been further developments in risk prediction. These and the present status of risk prediction in cl作者: 可耕種 時(shí)間: 2025-3-22 09:05 作者: 話(huà) 時(shí)間: 2025-3-22 13:10 作者: 話(huà) 時(shí)間: 2025-3-22 18:53 作者: byline 時(shí)間: 2025-3-23 01:02 作者: 弄臟 時(shí)間: 2025-3-23 04:28
archers, general practitioners, and primary care physicians.Cardiovascular disease is a major cause of morbidity and mortality in developed countries. Measurement of blood of lipids and lipoproteins has become one of the most frequently performed assays in clinical chemistry laboratories, reflecting作者: 不法行為 時(shí)間: 2025-3-23 07:12
https://doi.org/10.1007/978-3-8350-9259-4ausing coronary heart disease (CHD), cerebrovascular diseases and peripheral vascular diseases which here are called clinical atherosclerosis, cause considerable morbidity and disability. The major manifestations of clinical atherosclerosis are listed in Figure 1.1.作者: engrave 時(shí)間: 2025-3-23 11:16 作者: fatty-acids 時(shí)間: 2025-3-23 14:12
,Schlu?betrachtungen und Ausblick,d risk factor HDL-C [15]. Subsequently, there have been further developments in risk prediction. These and the present status of risk prediction in clinical atherosclerosis have recently been reviewed by Wilson [16], including an overview of the major different risk prediction algorithms (Figure 5.1).作者: 圣人 時(shí)間: 2025-3-23 18:16 作者: 角斗士 時(shí)間: 2025-3-24 01:39 作者: GROSS 時(shí)間: 2025-3-24 03:01 作者: 情感 時(shí)間: 2025-3-24 08:37
Lipid testing and prediction of coronary heart diseased risk factor HDL-C [15]. Subsequently, there have been further developments in risk prediction. These and the present status of risk prediction in clinical atherosclerosis have recently been reviewed by Wilson [16], including an overview of the major different risk prediction algorithms (Figure 5.1).作者: BALK 時(shí)間: 2025-3-24 12:44 作者: 殘暴 時(shí)間: 2025-3-24 17:54
Zielsetzung und Fragestellungen, of the risk associated with different lipid factors within a single patient cohort: the Women’s Health Study [20], the Framingham Offspring Study [21], the AMORIS new (second) study [22] and the INTERHEART study [7].作者: rectocele 時(shí)間: 2025-3-24 19:27 作者: Amnesty 時(shí)間: 2025-3-25 01:08
pose of lipid testing, diagnosis and lipid profiles as well as the goals of treatment and pharmacological management of lipid levels.The book is divided into two parts, one covering lipid testing and one covering lipid management in the prevention of cardiovascular disease.978-1-907673-03-0978-1-908517-33-3作者: 驚奇 時(shí)間: 2025-3-25 05:02 作者: superfluous 時(shí)間: 2025-3-25 11:23 作者: NATTY 時(shí)間: 2025-3-25 13:27
Drugs for lipid managementt-line treatment, however, it may well have to be combined with other. Lipid management drugs depending on the type of dyslipidaemia and the response to statins. It is worth noting that there is a residual risk after treatment with statins of clinical atherosclerosis events that varies between 40–60%.作者: Jacket 時(shí)間: 2025-3-25 18:54
Book 2011as the goals of treatment and pharmacological management of lipid levels.The book is divided into two parts, one covering lipid testing and one covering lipid management in the prevention of cardiovascular disease.作者: MIRTH 時(shí)間: 2025-3-25 21:55 作者: 修飾 時(shí)間: 2025-3-26 02:25 作者: 輕而薄 時(shí)間: 2025-3-26 04:34
https://doi.org/10.1007/978-1-908517-33-3Cholestrol; Coronary heart disease; Diabetes; Lipids; Statins作者: indignant 時(shí)間: 2025-3-26 10:48 作者: 銼屑 時(shí)間: 2025-3-26 15:09
Lars A. CarlsonWritten by a leading and highly respected expert in the field.Concise pocket-sized format.Particularly aimed at cardiologists, clinical researchers, general practitioners, and primary care physicians.作者: AMITY 時(shí)間: 2025-3-26 19:45
http://image.papertrans.cn/c/image/231972.jpg作者: GULF 時(shí)間: 2025-3-27 00:53
https://doi.org/10.1007/978-3-8350-5459-2here may now and then be a need for more intensive cholesterol lowering than can be achieved by the combination of TLC and drugs. Plasma apheresis (from the Greek, to take away), particularly LDL apheresis, can then be a life saving cholesterol-lowering treatment for patients with severe hypercholesterolaemia resistant to lipid drugs.作者: 華而不實(shí) 時(shí)間: 2025-3-27 02:41 作者: 枯燥 時(shí)間: 2025-3-27 06:54 作者: 放逐某人 時(shí)間: 2025-3-27 10:55
Strategisches Messemanagement im Wettbewerbs to determine LDL-C and HDL-C became available in routine clinical practice. Subsequently, attempts to advance the evaluation of risk for clinical atherosclerosis have continued, in order to improve prevention and treatment of the disease. In this respect, as described later in this chapter, two ma作者: cluster 時(shí)間: 2025-3-27 17:05
,Schlu?betrachtungen und Ausblick,erol, blood pressure, smoking and diabetes [14]. Risk prediction based on Framingham data was improved in the 1980s by addition of the ‘negative’ lipid risk factor HDL-C [15]. Subsequently, there have been further developments in risk prediction. These and the present status of risk prediction in cl作者: 帶來(lái)墨水 時(shí)間: 2025-3-27 21:40 作者: Arb853 時(shí)間: 2025-3-28 01:55
Unternehmensführung & Controlling used as a vitamin), and cholestyramine, a bile acid sequestrant. Both were effective in humans, had a dose-response effect on cholesterol levels and were difficult to manage, nicotinic acid because of its side-effect of facial flushing and cholestyramine because of the large doses required and beca作者: 抵押貸款 時(shí)間: 2025-3-28 02:32 作者: 珍奇 時(shí)間: 2025-3-28 08:38 作者: 傻瓜 時(shí)間: 2025-3-28 13:49 作者: 現(xiàn)存 時(shí)間: 2025-3-28 18:16
Strategisches MehrmarkencontrollingThe main purposes of lipid testing are:作者: cuticle 時(shí)間: 2025-3-28 19:14 作者: 圓柱 時(shí)間: 2025-3-28 23:34
https://doi.org/10.1007/978-3-8350-5459-2LDL-C is the primary target for lipid management. There are four major guidelines:作者: deadlock 時(shí)間: 2025-3-29 05:04 作者: engagement 時(shí)間: 2025-3-29 07:20 作者: BOLUS 時(shí)間: 2025-3-29 15:08 作者: Classify 時(shí)間: 2025-3-29 18:20
Lipid testingThe main purposes of lipid testing are:作者: hankering 時(shí)間: 2025-3-29 20:58
Goals of lipid managementThe three major clinical goals of lipid management are:作者: 過(guò)時(shí) 時(shí)間: 2025-3-30 03:11
Cholesterol goals in current guidelinesLDL-C is the primary target for lipid management. There are four major guidelines:作者: 觀點(diǎn) 時(shí)間: 2025-3-30 05:52 作者: TAG 時(shí)間: 2025-3-30 10:24 作者: 巧思 時(shí)間: 2025-3-30 16:09
Lipid-modifying agents under developmentThere are now several agents tailored for improving dyslipidaemic lipid profiles that have passed the preclinical testing and are presently in clinical trials. The two major fields for these new lipid drugs are:作者: 狂熱文化 時(shí)間: 2025-3-30 17:14
Ann C. Colleyfault zones in the forearc, accommodating tensional stress, as well as hydrothermal and mineral deposits, to mention a few. The following chapters emphasize on a variety of structures along continental margins and show the potential of deep EM in this geodynamic setting.作者: shrill 時(shí)間: 2025-3-30 22:36
Ye Wang,Hu Li,Hua Wang,Bin Zhou,Yanchun Zhang flight pattern, and stock prices and their evolution in time depend on a large number of factors that cannot be described by deterministic models. Problems that can be defined by algebraic, differential, and integral equations with random coefficients and/or input are referred to as stochastic prob作者: guardianship 時(shí)間: 2025-3-31 03:24
Conference proceedings 2021applications). The book will be beneficial for young as well as experienced researchers dealing across complex and intricate real-world problems for which finding a solution by traditional methods is a difficult task.作者: CLIFF 時(shí)間: 2025-3-31 08:37
https://doi.org/10.1007/978-1-4842-8989-1cuments represent the core ideas and concepts that have guided Belgrade’s urban development from 1867, the year marked as the turning point in the history of the modern urban development of Belgrade. It is the year in which the founder of modern Serbian urban planning, Emilijan Josimovi?, completed 作者: BADGE 時(shí)間: 2025-3-31 09:13
SpringerBriefs in Economicshttp://image.papertrans.cn/q/image/780933.jpg作者: Opponent 時(shí)間: 2025-3-31 16:58
Conference proceedings 2012of products, services, manufacturing systems, supply chain, consumption, as well as economics and society. EcoDesign 2011 - ?the 7th International Symposium on Environmentally Conscious Design and Inverse Manufacturing - was successfully held in the Japanese old capital city of Kyoto, on November 30
